Long-term utilization of immunosuppression in organ transplant recipients (OTRs) leads to
decreased immune-mediated tumor surveillance and development of malignant tumors. A
delicate balance needs to be maintained in the intensity of immunosuppression to keep the
risk of malignancy low without jeopardizing life-saving graft function. OTRs are prone to
developing skin cancers that exhibit unique epidemiologic, pathophysiologic, and
prognostic characteristics. In this review, we discuss the most commonly reported skin …